Biodexa Provides Update On Progression Free, Overall Survival In Phase 1 Study Of MTX110 In Recurrent Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
Biodexa provided an update on its Phase 1 study of MTX110 in recurrent glioblastoma, reporting on the progression-free and overall survival of patients in Cohort A. The study involves intermittent infusions of MTX110 via convection enhanced delivery. Two patients have deceased, while two others remain in follow-up.
October 04, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biodexa's update on the Phase 1 study of MTX110 in recurrent glioblastoma shows mixed results, with two patients deceased and two in follow-up. This may impact investor sentiment and stock price in the short term.
The update on the Phase 1 study of MTX110 in recurrent glioblastoma is significant for Biodexa as it provides insights into the drug's performance. The mixed results, with two patients deceased and two in follow-up, may lead to neutral investor sentiment, resulting in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100